2022: We reflect on the eventful year in our portfolio.

 

Looking forward into the new year, a key priority is to support our existing portfolio companies in navigating these challenging times and continuing their growth. With the increased € 500 Million mandate of our new fund, we will continue to re-invest in our entire portfolio, but our strategy for new company investments in 2023 will be to focus uniquely on Danish-based science. Denmark is in our DNA, and we want to nurture the local ecosystem. We are really excited to be bringing Danish discoveries to the lives of patients worldwide – bring on 2023!
 

The New Team – and still expanding

Earlier this year, we welcomed several new colleagues to further strengthen the expertise of the team. The newest addition to the team is Liane Dupont.
Liane Dupont, Associate, joins from an academic research career in the United Kingdom, most recently at King’s College London. She has led and contributed to research into coronavirus biology at the molecular and clinical level. She brings strong academic research experience, particularly in the infectious disease space, and has published in numerous high-ranking journals such as Nature Microbiology and Cell Host & Microbe.

In 2023, we are looking to expand the team and will be looking for a person to fill the position as Associate. Keep an eye out on our website and LinkedIn, where the job ad will be posted. 

 

Portfolio Highlights

The last 12 months have been challenging from both a private and public market perspective, yet the BioCapital portfolio companies have managed to continue performing well in advancing their pipelines. Below, we have handpicked a selection of successes – among many – to share with you.

NMD Pharma reports positive top-line data from a Phase I/IIa clinical trial of NMD670 in patients with Myasthenia Gravis (MG): NMD Pharma develops treatments for neuromuscular diseases. The data provide first clinical proof of the mechanism of action of NMD670, a ClC-1 chloride ion channel inhibitor. NMD670 restored neuromuscular function leading to clinical meaningful effects even with a single dose in patients with myasthenia gravis. This provides a unique translational platform for NMD Pharma and informs new clinical studies in additional indications characterized by neuromuscular dysfunction. Also, a big congratulations to NMD Pharma and the team for winning the ‘EY Entrepreneur Of The Year 2022’ award in the category of Life Sciences. (Photo: EY.com)

SNIPR Biome doses the first human subjects in its Phase I clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic: SNIPR Biome, a leading CRISPR and microbiome gene therapy biotech company, is developing CRISPR based therapeutics with the goal of modulating the human microbiome through precision elimination of pathogenic bacteria and gene editing of the microbiome. SNIPR001 is designed to selectively eradicate fluoroquinolone resistant E. coli in the gut, thus preventing bloodstream infections. This will address the high-risk population of hematological cancer patients at risk for neutropenia. This precision approach could transform the way bacterial infections are prevented and treated.

Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new immunotherapies for food allergies and inflammatory bowel disease (IBD): Enterome is pioneering the development of novel microbiome-based drugs to treat cancer and GI tract disorders. Under the agreement with Nestlé Health Science, they will co-develop Enterome’s lead EndoMimics™ compound, EB1010, a potent local inducer of IL-10 targeting food allergies and IBD. EB1010 is due to enter clinical trials in 2023. The collaboration will also create a pipeline of novel AllerMimics™ candidates that mimic food allergens to generate immune tolerance and identify new EndoMimics™ that reduce inflammation caused by food allergies. The collaboration further validates Enterome’s highly productive Mimicry platform that has already demonstrated clinical efficacy with the OncoMimics™ immunotherapy pipeline for cancer.

scPharmaceuticals receives FDA approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for at-home treatment of congestion in chronic heart failure: scPharmaceuticals is developing and commercializing products that optimize the delivery of infused therapies, advancing patient care and reducing healthcare costs. FUROSCIX® is a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. FUROSCIX® is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home. Commercial launch is planned in Q1 2023.

IO Biotech initiates Phase III  combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanoma: IO Biotech is developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The Phase III trial seeks to evaluate IO Biotech’s lead candidate, IO102-IO103, in combination with KEYTRUDA® in patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Furthermore, IO Biotech has initiated a Phase II trial of IO102-IO103 in combination with KEYTRUDA® as first-line treatment in a multi-arm basket trial.  Also, a big congratulation to Mai-Britt Zocca, President and CEO of IO Biotech, for winning the ‘Women-led Business Leader of the Year’ award given by European Lifestars Awards. (Photo: IO Biotech)